Pieris Pharmaceuticals Inc. (PIRS): Skating on Thin Ice? We Know the Answer

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) went up by 8.71% from its latest closing price compared to the recent 1-year high of $3.64. The company’s stock price has collected 11.67% of gains in the last five trading sessions. Press Release reported on 03/30/21 that Thinking about buying stock in Academy Sports & Outdoors, Ion Geophysical, Pieris Pharmaceuticals, Energous Corp, or FreightCar America?

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Is It Worth Investing in Pieris Pharmaceuticals Inc. (NASDAQ :PIRS) Right Now?

Plus, the 36-month beta value for PIRS is at 1.27. Opinions of the stock are interesting as 3 analysts out of 3 who provided ratings for Pieris Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.


The average price from analysts is $9.00. PIRS currently public float of 55.92M and currently shorts hold a 4.21% ratio of that float. Today, the average trading volume of PIRS was 487.64K shares.

PIRS’s Market Performance

PIRS stocks went up by 11.67% for the week, with a monthly jump of 8.30% and a quarterly performance of 5.13%, while its annual performance rate touched 11.24%. The volatility ratio for the week stands at 6.66% while the volatility levels for the past 30 days are set at 7.29% for Pieris Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is 9.35% for PIRS stocks with a simple moving average of 4.70% for the last 200 days.

Analysts’ Opinion of PIRS

Many brokerage firms have already submitted their reports for PIRS stocks, with Robert W. Baird repeating the rating for PIRS by listing it as a “Outperform.” The predicted price for PIRS in the upcoming period, according to Robert W. Baird is $5 based on the research report published on March 13th of the previous year 2020.

Robert W. Baird gave a rating of “Outperform” to PIRS, setting the target price at $5 in the report published on May 14th of the previous year.

PIRS Trading at 5.62% from the 50-Day Moving Average

After a stumble in the market that brought PIRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.13% of loss for the given period.

Volatility was left at 7.29%, however, over the last 30 days, the volatility rate increased by 6.66%, as shares surge +12.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.36% upper at present.

During the last 5 trading sessions, PIRS rose by +11.67%, which changed the moving average for the period of 200-days by -14.84% in comparison to the 20-day moving average, which settled at $2.64. In addition, Pieris Pharmaceuticals Inc. saw 14.80% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at PIRS starting from Aquilo Capital Management, LLC, who sale 1,900,000 shares at the price of $2.95 back on Jul 21. After this action, Aquilo Capital Management, LLC now owns 3,675,530 shares of Pieris Pharmaceuticals Inc., valued at $5,605,000 using the latest closing price.

Stock Fundamentals for PIRS

Current profitability levels for the company are sitting at:

  • -115.68 for the present operating margin

The net margin for Pieris Pharmaceuticals Inc. stands at -126.97. The total capital return value is set at -59.24, while invested capital returns managed to touch -65.43. Equity return is now at value -87.00, with -32.20 for asset returns.

Based on Pieris Pharmaceuticals Inc. (PIRS), the company’s capital structure generated 51.35 points at debt to equity in total, while total debt to capital is 33.93. Total debt to assets is 15.17, with long-term debt to equity ratio resting at 51.35. Finally, the long-term debt to capital ratio is 33.93.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

When we switch over and look at the enterprise to sales, we see a ratio of 2.79, with the company’s debt to enterprise value settled at 0.20. The receivables turnover for the company is 6.91 and the total asset turnover is 0.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.42.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Important Earnings

Insider Watchlist

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.